Erythropoiesis-Stimulating Agent Treatment in Patients With COVID-19.

Fishbane, Steven; Hirsch, Jamie S

Fishbane, Steven; Hirsch, Jamie S.

Fishbane S; Division of Kidney Diseases and Hypertension, Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY. Electronic address: sfishbane@northwell.edu.
Hirsch JS; Division of Kidney Diseases and Hypertension, Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY.

Am J Kidney Dis ; 76(3): 303-305, 2020 09.

Article in English | MEDLINE | ID: covidwho-436941

Subject(s)

Betacoronavirus; Coronavirus Infections/drug therapy; Erythropoiesis/drug effects; Hematinics/therapeutic use; Pneumonia, Viral/drug therapy; Acute Kidney Injury/blood; Acute Kidney Injury/drug therapy; Acute Kidney Injury/epidemiology; Anemia/blood; Anemia/drug therapy; Anemia/epidemiology; COVID-19; Coronavirus Infections/blood; Coronavirus Infections/epidemiology; Erythropoiesis/physiology; Erythropoietin/blood; Hematinics/pharmacology; Humans; Pandemics; Pneumonia, Viral/blood; Pneumonia, Viral/epidemiology; SARS-CoV-2; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Erythropoiesis / Betacoronavirus / Hematinics Type of study: Observational study / Prognostic study Limits: Humans Language: English Journal: Am J Kidney Dis Year: 2020 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google